Back to Find a Doctor
Elliott F. Winton

Elliott F. Winton, MD

Dr. Winton’s research has focused on understanding normal and malignant hematopoiesis at the bench and bedside. At the bedside, he has conducted clinical trials to test the effects of novel therapies and improved supportive care for treating myeloid malignancies, collaborated in establishing the first hematopoietic stem cell transplantation program in Georgia, and conducted studies to improve understanding of several hematologic disease entities (e.g. discovery of hemoglobin Atlanta, studies on large granular lymphocytic leukemia, frequent occurrence of copper deficiency masquerading as myelodysplasia). Laboratory and animal-based projects included methods to better quantify in vitro and in vivo granulopoiesis, granulopoietic growth factor perturbations during murine marrow regeneration, and the development of preclinical models for studying newly introduced recombinant human hematopoietic growth factors using the rhesus macaque.

Dr. Winton is a member of the American Society of Hematology and the American Society of Clinical Oncology. He earned his Medical Degree from the University of Chicago Pritzker School of Medicine, where he completed his Internship as well. He then went on to complete his Residency and Fellowship at the Emory University Affiliated Hospitals.

Specialties

  • Internal Medicine

Board Certifications

  • ABMS Internal Medicine

Fellowships

  • Emory University School of Medicine

Affiliations

  • Emory

Education & Training

  • Medical School: University of Chicago Pritzker School of Medicine
  • Internship: University of Chicago Hospitals
  • Residency: Grady Health System

Honors & Awards

2016 MPN (Myeloproliferative Neoplasms) Hero Award

Emory University School of Medicine MilliPub Club

Publications

https://pubmed.ncbi.nlm.nih.gov/?term=Winton%20EF%5Bauth%5D

Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia. Jillella AP Arellano ML Gaddh M Langston AA Heffner LT Winton EF, McLemore ML Zhang C Caprara CR Simon KS Bolds SL DeBragga S Karkhanis P Krishnamurthy SH Tongol J El Geneidy MM Pati A Gerber JM Grunwald MR Cortes J Bashey A Stuart RK Kota VK . JCO oncology practice OP2000395 2020-10-30

Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera. Coltoff A Mesa R Gotlib J Shulman J Rampal RK Siwoski O Yacoub A Moliterno A Yang A Braunstein E Gerds AT Hobbs GS Winton EF, Goel S Wadleigh M Tremblay D Moshier E Mascarenhas J . Clinical lymphoma, myeloma & leukemia 20 10 697-703.e1 2020-10-01

Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors. Kong JH Winton EF, Heffner LT Gaddh M Hill B Neely J Hatcher A Joseph M Arellano M El-Rassi F Kim A Khoury JH Kota VK . Journal of clinical medicine 9 5 2020-05-20

Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Yacoub A Mascarenhas J Kosiorek H Prchal JT Berenzon D Baer MR Ritchie E Silver RT Kessler C Winton E, Finazzi MC Rambaldi A Vannucchi AM Leibowitz D Rondelli D Arcasoy MO Catchatourian R Vadakara J Rosti V Hexner E Kremyanskaya M Sandy L Tripodi J Najfeld V Farnoud N Papaemmanuil E Salama M Singer-Weinberg R Rampal R Goldberg JD Barbui T Mesa R Dueck AC Hoffman R . Blood 134 18 1498-1509 2019-10-31

Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease. Khoury HJ Langston AA Kota VK Wilkinson JA Pusic I Jillella A Bauer S Kim AS Roberts D Al-Kadhimi Z Bodo I Winton E, Arellano M DiPersio JF . Bone marrow transplantation 53 7 826-831 2018-07-01

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Harrison CN Vannucchi AM Platzbecker U Cervantes F Gupta V Lavie D Passamonti F Winton EF, Dong H Kawashima J Maltzman JD Kiladjian JJ Verstovsek S . The Lancet. Haematology 5 2 e73-e81 2018-02-01

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis. Mesa RA Kiladjian JJ Catalano JV Devos T Egyed M Hellmann A McLornan D Shimoda K Winton EF, Deng W Dubowy RL Maltzman JD Cervantes F Gotlib J . Journal of clinical oncology : official journal of the American Society of Clinical Oncology 35 34 3844-3850 2017-12-01

Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective Switch From Second-Generation Tyrosine Kinase Inhibitor to Imatinib. Kota VK Kong JH Arellano M El Rassi F Gaddh M Heffner LT Winton EF, Jillella AP McLemore ML Khoury HJ . Clinical lymphoma, myeloma & leukemia 17 12 e71-e73 2017-12-01

Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia? Kong JH Winton EF, Heffner LT Chen Z Langston AA Hill B Arellano M El-Rassi F Kim A Jillella A Kota VK Bodó I Khoury HJ . Cancer 123 13 2482-2488 2017-07-01

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Harrison CN Schaap N Vannucchi AM Kiladjian JJ Tiu RV Zachee P Jourdan E Winton E, Silver RT Schouten HC Passamonti F Zweegman S Talpaz M Lager J Shun Z Mesa RA . The Lancet. Haematology 4 7 e317-e324 2017-07-01

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. Verstovsek S Mesa RA Gotlib J Gupta V DiPersio JF Catalano JV Deininger MW Miller CB Silver RT Talpaz M Winton EF, Harvey Jr JH Arcasoy MO Hexner EO Lyons RM Paquette R Raza A Jones M Kornacki D Sun K Kantarjian H . Journal of hematology & oncology 10 1 55 2017-02-22

Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia. Winton EF, Kota V . Future oncology (London, England) 13 5 395-407 2017-02-01

Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Mascarenhas JO Talpaz M Gupta V Foltz LM Savona MR Paquette R Turner AR Coughlin P Winton E, Burn TC O'Neill P Clark J Hunter D Assad A Hoffman R Verstovsek S . Haematologica 102 2 327-335 2017-02-01

Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma. Cohen JB Bucur S, Winton EF Sinha R Heffner LT King N Lonial S Langston AA Waller EK Hutchison-Rzepka A Colbert A Lechowicz MJ Flowers CR . Clinical lymphoma, myeloma & leukemia 15 9 514-8 2015-09-01

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Verstovsek S, Mesa RA Gotlib J Levy RS Gupta V DiPersio JF Catalano JV Deininger MW Miller CB Silver RT Talpaz M Winton EF Harvey Jr JH Arcasoy MO Hexner EO Lyons RM Raza A Vaddi K Sun W Peng W Sandor V Kantarjian H . Haematologica 100 4 479-88 2015-04-01

Predicting early blast transformation in chronic-phase chronic myeloid leukemia: is immunophenotyping the missing link? El Rassi F Bergsagel JD Arellano M Gaddh M Jillella A Kota V Heffner LT Winton EF Khoury HJ, . Cancer 121 6 872-5 2015-03-15

Incidence and geographic distribution of adult acute leukemia in the state of Georgia. El Rassi F Ward KC Flowers CR Heffner LT Waller EK, Winton EF Vaughn J Hill BG Langston A Nooka A Arellano M Khoury HJ . Southern medical journal 107 8 497-500 2014-08-01

Sensitivity and specificity of cerebrospinal fluid flow cytometry for the diagnosis of leukemic meningitis in acute lymphoblastic leukemia/lymphoma. Mitri Z Siddiqui MT El Rassi F Holden JT Heffner LT Langston A Waller EK Winton E McLemore M Bernal-Mizrachi L Jaye D Arellano M Khoury HJ, . Leukemia & lymphoma 55 7 1498-500 2014-07-01

Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Mesa RA Kiladjian JJ Verstovsek S Al-Ali HK Gotlib J Gisslinger H Levy R Siulnik A Gupta V Khan M DiPersio JF McQuitty M Catalano JV Hunter DS Knoops L Deininger M Cervantes F Miller C Vannucchi AM Silver RT Barbui T Talpaz M Barosi G Winton EF, Mendeson E Harvey Jr JH Arcasoy MO Hexner E Lyons RM Paquette R Raza A Sun W Sandor V Kantarjian HM Harrison C . Haematologica 99 2 292-8 2014-02-01

Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia. Dao KH, Solti MB Maxson JE Winton EF Press RD Druker BJ Tyner JW . Leukemia research reports 3 2 67-9 2014-01-01

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Verstovsek S Mesa RA Gotlib J Levy RS Gupta V DiPersio JF Catalano JV Deininger MW Miller CB Silver RT Talpaz M Winton EF, Harvey Jr JH Arcasoy MO Hexner EO Lyons RM Paquette R Raza A Vaddi K Erickson-Viitanen S Sun W Sandor V Kantarjian HM . Haematologica 98 12 1865-71 2013-12-01

Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. Antun AG Gleason S Arellano M Langston AA McLemore ML Gaddh M el Rassi F Bernal-Mizrachi Jr L Galipeau J, Heffner LT Winton EF Khoury HJ . Cancer 119 21 3784-7 2013-11-01

The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. Verstovsek S Mesa RA Gotlib J Levy RS Gupta V DiPersio JF Catalano JV Deininger M Miller C Silver RT Talpaz M Winton EF, Harvey Jr JH Arcasoy MO Hexner E Lyons RM Paquette R Raza A Vaddi K Erickson-Viitanen S Sun W Sandor V Kantarjian HM . British journal of haematology 161 4 508-16 2013-05-01

Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. Mesa RA Gotlib J Gupta V Catalano JV Deininger MW Shields AL Miller CB Silver RT Talpaz M Winton EF, Harvey JH Hare T Erickson-Viitanen S Sun W Sandor V Levy RS Kantarjian HM Verstovsek S . Journal of clinical oncology : official journal of the American Society of Clinical Oncology 31 10 1285-92 2013-04-01

Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia. Arellano M Pakkala S Langston A Tighiouart M Pan L Chen Z Heffner LT Lonial S, Winton E Khoury HJ . Cancer 118 21 5278-82 2012-11-01

Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase. Muringampurath-John D Jaye DL Flowers CR Saxe D Chen Z Lechowicz MJ Weisenburger DD Bast M Arellano ML Bernal-Mizrachi L Heffner LT, McLemore M Kaufman JL Winton EF Lonial S Armitage JO Khoury HJ . British journal of haematology 158 5 608-14 2012-09-01

Managing chronic myeloid leukemia: a coordinated team care perspective. Holloway S Lord K Bethelmie-Bryan B, Shepard MW Neely J McLemore M Reddy SK Montero A Jonas WS Gladney SP Khanwani SL Reddy SC Lahiry AK Heffner LT Winton E Arellano M Khoury HJ . Clinical lymphoma, myeloma & leukemia 12 2 88-93 2012-04-01

Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma. Muringampurath-John D Flowers CR Toscano M Zhengjia C Kaufman JL Arellano M Bernal-Mizrachi L Heffner LT Lechowicz MJ McLemore M Winton E Jaye DL Lonial S Khoury HJ, . Leukemia & lymphoma 53 4 725-7 2012-04-01

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. Verstovsek S Mesa RA Gotlib J Levy RS Gupta V DiPersio JF Catalano JV Deininger M Miller C Silver RT Talpaz M Winton EF, Harvey Jr JH Arcasoy MO Hexner E Lyons RM Paquette R Raza A Vaddi K Erickson-Viitanen S Koumenis IL Sun W Sandor V Kantarjian HM . The New England journal of medicine 366 9 799-807 2012-03-01

High-dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 years. Arellano M Winton E, Pan L Lima L Tighiouart M Bhalla K Heffner LT Neely J Hutcherson D McLemore M Langston A Khoury HJ . Cancer 118 2 428-33 2012-01-15

Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia. Arellano M Bernal-Mizrachi L Pan L Tighiouart M Souza L Guo X McLemore M Lima L Sunay S, Heffner LT Chen Z Chen GZ Langston A Winton E Khoury HJ . Clinical lymphoma, myeloma & leukemia 11 5 427-32 2011-10-01

Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia? Lima LM Sampat K Assouline S Saxe D Nault S, Tighiouart M McLemore M Arellano M Winton E Bernal-Mizrachi L Cortes J Khoury HJ . Leukemia & lymphoma 52 6 1010-6 2011-06-01

Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond. Lima L Bernal-Mizrachi L Saxe D Mann KP Tighiouart M Arellano M Heffner L McLemore M Langston A, Winton E Khoury HJ . Cancer 117 6 1245-52 2011-03-15

Deep venous thromboses in patients with hematological malignancies after peripherally inserted central venous catheters. Tran H Arellano M Chamsuddin A Flowers C Heffner LT Langston A Lechowicz MJ, Tindol A Waller E Winton EF Khoury HJ . Leukemia & lymphoma 51 8 1473-7 2010-08-01

Spectrum of FDG PET/CT findings in Burkitt lymphoma. Zeng W Lechowicz MJ, Winton E Cho SM Galt JR Halkar R . Clinical nuclear medicine 34 6 355-8 2009-06-01

Acquired copper deficiency: a potentially serious and preventable complication following gastric bypass surgery. Griffith DP, Liff DA Ziegler TR Esper GJ Winton EF . Obesity (Silver Spring, Md.) 17 4 827-31 2009-04-01

Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma. Murali S Winton E, Waller EK Heffner LT Lonial S Flowers C Kaufman J Arellano M Lechowicz MJ Mann KP Khoury HJ Langston AA . Bone marrow transplantation 42 8 529-34 2008-10-01

Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma. Lonial S Arellano M Hutcherson D Langston A Flowers C Heffner LT Winton E, Jo Lechowicz M Waller EK . Leukemia & lymphoma 47 10 2155-62 2006-10-01